Extrahepatic Bile Duct Adenocarcinoma — knowledge graph · CancerIndex

Knowledge graph · Cancer

Extrahepatic Bile Duct Adenocarcinoma

subtype

Identifier: CI-CAN-00008874
Entity page: /cancer/extrahepatic-bile-duct-adenocarcinoma ↗
Edges: 18

Neighbours: 11 drugs7 trials
Drawn: 18 of 18 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Extrahepatic Bile Duct Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived11 of 11
→ investigated in trials for	Sorafenib Tosylatesmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Extrahepatic Bile Duct Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants

Extrahepatic Bile Duct Adenocarcinoma studied in …STUDIED_INderived7 of 7
→ studied in	NCT05285358Phase 1 · recruiting Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases · condition mapped ONTOLOGY_EXACT · 7 trials mapped (3 active)	—	—	Distal Bile Duct Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03257761Phase 1 · active not recruiting Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer · condition mapped ONTOLOGY_EXACT · 7 trials mapped (3 active)	—	—	Extrahepatic Bile Duct Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04941287Phase 2 · active not recruiting Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer · condition mapped CURATED_BROADER · 7 trials mapped (3 active)	—	—	Distal Bile Duct Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00478140Phase 2 · terminated Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery · condition mapped ALIAS · 7 trials mapped (3 active)	—	—	Extrahepatic Bile Duct Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00085410Phase 2 · terminated Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder · condition mapped ALIAS · 7 trials mapped (3 active)	—	—	Extrahepatic Bile Duct Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01093222Phase 2 · completed Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma · condition mapped ONTOLOGY_EXACT · 7 trials mapped (3 active)	—	—	Extrahepatic Bile Duct Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00238212Phase 2 · completed S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma · condition mapped ALIAS · 7 trials mapped (3 active)	—	—	Extrahepatic Bile Duct Adenocarcinoma	1	Observed	clinicaltrials	graph →